tirzepatide vs semaglutide clinical trials 2026: 22% vs 15% Weight Loss Guide EASD 2023: meta-analysis shows tirzepatide

The stated intent is to dramatically increase access for patients who need to lose weight

[DOI] [PMC free article] [PubMed] [Google Scholar] 69.Vairetti M., Di Pasqua L.G., Cagna M., Richelmi P., Ferrigno A., Berardo C

At present, the studies of EX on non-diabetic obesity mainly include 152 cases of simple obesity (weight loss of 5.1 kg) (54), 60 cases of polycystic ovary syndrome (weight loss of 3.2-6.0 kg) (55), and 10 cases of metabolic syndrome (weight loss of 3.7 kg) (56), among which the most common adverse reaction is still vomiting

Joshua Long MD, MBA, FACS, FASMBS A nationally renowned and double-board-certified Denver bariatric surgeon, Dr